Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR…
BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
MELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”,…
EssilorLuxottica: Third-Quarter 2025 Revenue Conference Call Invitation
Third-Quarter 2025 RevenueConference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, andMr…
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinsons Disease and Movement Disorders
– ARV-102 was well tolerated in clinical trials for both healthy volunteers…
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety…
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
October 05, 2025 09:00 ET | Source: Spyre Therapeutics, Inc. WALTHAM, Mass.,…
Spyre Therapeutics Announces Grants of Inducement Awards
October 03, 2025 16:05 ET | Source: Spyre Therapeutics, Inc. WALTHAM, Mass.,…
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”),…
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025 16:01 ET | Source: Intellia Therapeutics, Inc. CAMBRIDGE, Mass.,…
